The agreement covers 129 countries, including all African nations, and gives Aspen rights across both public and private healthcare sectors.
Through the proposed partnership, Africa CDC and Aspen plan to establish a multi-year collaboration to boost local manufacturing capacity, improve supply security, and create sustainable markets for African-made vaccines.
The sale came about following an unsolicited offer from BGH Capital, which focuses on investments in Australia and New Zealand.